Certara, Inc. (NASDAQ:CERT) Receives Consensus Rating of “Hold” from Analysts

Certara, Inc. (NASDAQ:CERT) has been given a consensus rating of “Hold” by the thirteen ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $8.85.

CERT has been the subject of several research reports. Morgan Stanley reduced their target price on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Certara in a research note on Friday, May 29th. Barclays cut their price target on Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Craig Hallum reduced their price objective on Certara from $10.00 to $8.00 and set a “hold” rating for the company in a research report on Tuesday, May 12th. Finally, KeyCorp decreased their price objective on Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a report on Monday, April 13th.

Certara Stock Performance

CERT stock traded down $0.02 on Friday, reaching $6.77. 5,392,337 shares of the company were exchanged, compared to its average volume of 4,643,270. The firm has a market capitalization of $1.05 billion, a PE ratio of -67.70 and a beta of 1.46. Certara has a 12 month low of $4.45 and a 12 month high of $13.88. The stock’s fifty day moving average price is $5.70 and its 200 day moving average price is $6.78. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The company had revenue of $106.92 million during the quarter, compared to the consensus estimate of $106.13 million. Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. Certara’s revenue for the quarter was up .8% on a year-over-year basis. During the same period last year, the company earned $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, research analysts anticipate that Certara will post 0.24 EPS for the current fiscal year.

Institutional Trading of Certara

Several institutional investors have recently made changes to their positions in the business. Osaic Holdings Inc. raised its holdings in shares of Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after buying an additional 1,175 shares in the last quarter. Corient Private Wealth LLC raised its stake in shares of Certara by 11.7% in the second quarter. Corient Private Wealth LLC now owns 12,362 shares of the company’s stock worth $144,000 after acquiring an additional 1,295 shares during the last quarter. Central Pacific Bank Trust Division lifted its position in shares of Certara by 8.7% during the second quarter. Central Pacific Bank Trust Division now owns 19,460 shares of the company’s stock worth $127,000 after purchasing an additional 1,558 shares in the last quarter. Treasurer of the State of North Carolina lifted its position in shares of Certara by 2.9% during the second quarter. Treasurer of the State of North Carolina now owns 56,628 shares of the company’s stock worth $663,000 after purchasing an additional 1,597 shares in the last quarter. Finally, Nicolet Advisory Services LLC grew its stake in shares of Certara by 7.4% during the third quarter. Nicolet Advisory Services LLC now owns 30,608 shares of the company’s stock valued at $396,000 after purchasing an additional 2,100 shares during the last quarter. 73.96% of the stock is currently owned by institutional investors and hedge funds.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.